International Journal of General Medicine and Pharmacy (IJGMP)
ISSN(P): 2319–3999; ISSN(E): 2319–4006
Vol. 10, Issue 1, Jan–Jun 2021; 15–32

International Academy of Science, Engineering and Technology
Connecting Researchers; Nurturing Innovations

MANAGEMENT OF INFERTILITY IN POLYCYSTIC OVARIAN SYNDROME

Vrish Dhwaj Ashwlayan[1], Gursimran Kaur[2] & Divya Sharma[3]

[1]M. Pharm. (Pharmacology), Ph.D., Professor, Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, NH-58, Meerut, Uttar Pradesh, India

[2]M. Pharm. (Pharmacology) Research Scholar, CSIR-CIMAP Lucknow, Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, Uttar Pradesh, India

[3]Ph.D., Head of Department, Department of Computer Science, Deva Nagri College Meerut, Uttar Pradesh, India

ABSTRACT

Polycystic ovarian condition (PCOS) is most commonly known endocrine problems among women of psychological generation. It presents, for the most part, sporadic menstrual cycles, signs of hyper-androgenism and insulin resistance. Patients with PCOS are at increased risk for regenerative, metabolic and cardiovascular problems, such as fruitlessness, insulin obstruction, type II diabetes mellitus, The PCOS board expects to decrease body weight and insulin level, restore fruitfulness, manage excess hair growth on the body or scalp, re-establish the normal feminine cycle, and forestall confusions. Insulin sensitizers have been among the primary metabolic modulators with inconsistent performance. Insulin opposition, followed by thiazolidinediones, is central to the pathophysiology of PCOS, with virtually equal viability to metformin. Statins and incretins comprise novel treatments with unmistakable metabolic targets guarantee in the administration of PCOS. Nutrient D, acarbose and myoinositol, a large group of reciprocal and elective clinical treatments have guarantee in the administration of PCOS. The helpful choices for overseeing PCOS-related fruitlessness have additionally extended. Clomiphene citrate (CC) has for quite some time been the primary line methodology for ovulation enlistment in the setting of an ovulatory fruitlessness; in any case, aromatase inhibitors actuate an ovulation, with results practically identical or far better than those seen with CC. An expanding level of remedial advancement is reflected in ovarian incitement conventions sensibly utilizing gonadotropins, gonadotropin-delivering hormone rivals, the strategy of ovarian boring and helped conceptive advances with in-vitro oocyte development.

KEYWORDS: *Polycystic Ovarian Condition, Aromatase Inhibitors, Hyperandrogenism, Clomiphene Citrate, Glucocorticoids*

Article History

Received: *03 May 2021* **|** ***Revised:*** *10 May 2021* **|** ***Accepted:*** *12 May 2021*

INTRODUCTION

The impression "Polycystic ovaries" suggests to the numerous little blisters, or knocks, in the ovaries. Polycystic Ovarian disorder (PCOS), otherwise called Polycystic Ovary Disease (PCOD) is an exceptionally regular condition influencing 5% to 10% of ladies in the age bunch 12-45 years. It is an issue wherein a lady's hormones are out of parity. It can cause issues with menstrual periods and make it hard for her to consider. The chief highlights incorporate no ovulation, sporadic periods, skin inflammation and hirsutism. It can induce insulin-safe diabetes, weight and elevated cholesterol that prompt heart disease if not treated. Stein-Leventhal disease, realistic ovarian hyperandrogenism, ovarian hyperthecosis,

sclerocystic ovary disease, and polycystic ovary malady are some terms for this condition. The disease was first portrayed in 1935 by American gynaecologists Irving F Stein and Michael L Leventhal, for which Stein Leventhal disorder took its distinctive name[1,2-3].In 1721 in Italy, the first transmitted representation of a patient with what is commonly perceived as PCOS was. In 1844[4], blister based improvements to the ovaries were depicted[4]. It is believed to be one of the main sources of female sub-fertility and the most regular endocrine issue in ladies of conceptive age[5,6]. The fundamental highlights of PCOS are an ovulation, hyper-androgenism and insulin opposition. Anovulation brings about unpredictable feminine cycle, amenorrhea, ovulation-related fruitlessness and polycystic ovaries. Hyper-androgenism, a medical condition characterized by high levels of androgens in females brings about skin inflammation and hirsutism. Insulin obstruction is regularly connected with weight, Type-II diabetes, and elevated levels of cholesterol. The side effects and seriousness of the disorder shift extraordinarily among the influenced ladies. Besides, it might influence day by day physical exercises[7].Women with PCOS have variations from the norm in the digestion of androgens and oestrogen and in the control of androgen creation. A lady is determined to have polycystic ovaries (instead of PCOS) on the off chance that she has at least 12 follicles in one ovary.

Aetiology

Hormone lopsidedness, Insulin opposition (the body can't utilize insulin appropriately) and high testosterone (the body delivers an excess of testosterone) causes the side effects of PCOS. Polycystic ovarian disorder is an endocrine disorder whose pathophysiology is muddled. Hereditary and natural benefactors consolidate to lead to the aetiology of PCOS[8,9] with heaviness, ovarian brokenness and hormonal motors. A lack of ideal methods to survey either hyperandrogenism or insulin obstruction has hindered better awareness of the cause. In about 60 %-80 % of women with PCOS, hyperandrogenism is recognised, and insulin opposition is a pathophysiological supporter in around half 80 %[10]. Solidness increments philosophical characteristics confusions with hyperandrogenism, hirsutism, stubbornness and parenting-both openly and by PCOS intensification[11,12]. Moreover, weight worsens the PCOS-related expanded hazard factors for disabled glucose resilience, Diabetes Mellitus Type-II and Cardiovascular Disease[13], while over-weight influences mental highlights of PCOS.

Pathogenesis of PCOS

Polycystic ovaries produce, as the ovaries are animated to produce excessive measurements of male hormones (androgens), particularly testosterone, either through the introduction of exorbitant luteinizing hormone by the primary pituitary organ, elevated levels of insulin in the blood (hyper-insulinemia) in women whose ovaries are susceptible to this upgrade or decreased levels of globulin-resistant sex hormone[14]. Due to the daily sign on ultrasound examination of distinct ovarian pimples that talk to youthful follicles, the condition obtained its name. Due to the upset ovarian ability, the follicles have produced follicles from the early stage but the progress has stopped at an early antral point. The follicles could be located around the ovarian fringe showing up on ultrasound examination as a 'pearl necklace[15]. Patients with PCOS have higher hormone-delivering gonadotrophin (GnRH), resulting in an improvement in the proportion of LH/FSH in females with PCOS. The bulk of PCOS patients have insulin resistance and extra weight. Their elevated levels of insulin contribute to or cause deviations in the hypothalamic-pituitary-ovarian pivot from the norm that lead to PCOS. Hyper-insulinemia builds recurrence of GnRH hit, LH over predominance of FSH, increased androgen formation of ovaries, decreased follicular production and decreased authoritarian SHBG. The development of PCOS[16,17] is complemented by each of these variables. A mind-boggling positive feedback of insulin opposition and hyperandrogenism is defined as PCOS. Many of the time, it

is not possible to address which of the two should be respected as the causative expert. Trial therapy for all androgens enemies and insulin sharpening operators increases all hyper-androgenicity and insulin opposition[18]. Aromatase, a compound that switches from androstenedione to estrone and testosterone to estradiol, is present in fat tissue. In corpulent patients, the overabundance of fat tissue renders them both excess androgens (responsible for hirsutism and virilization) and estrogens (repressing FSH by means of derogatory input)[19].

PCOS can be associated with continuous ovarian agitation, which can contribute to improvements in adherence, endocrine and metabolism that may be prone to PCOS. The fiery arbiters and oxidative concern are correlated with an ovulation and multiple PCOS signs in a few examinations[20]. Recently it was indicated that a decreased serum level of insulin-like production factor restricting protein-1 (IGFBP-1) could contribute to the over-the-top androgen generation in PCOS, thus extending the degree of free IGF-1 that boosts ovarian androgen generation, but late information ends up making this mechanism unlikelyIn addition, PCOS has been correlated with a specific subgenotype of delicate X behavioural hindrance 1 (FMR1). Numerous studies have reported that women with heterozygous-typical / low FMR1 have polycystic-like signs of intense follicle activity and hyperactive ovarian ability[21-22].

Pathophysiology

Adjustments in gonadotropin-delivering hormone (GnRH) pulsatility lead to special creation of luteinizing hormone (LH) contrasted and follicle-invigorating hormone (FSH). LH animates ovarian androgen creation, while the overall scarcity of FSH forestalls satisfactory incitement of aromatase action inside the granulosa cells, consequently diminishing androgen change to the powerful ooestrogen estradiol. Expanded intrafollicular androgen levels bring about follicular atresia. Absence of follicular advancement brings about an ovulation and therefore oligo-amenorrhea. Raised serum androgens (basically androstenedione) are changed over in the fringe to oestrogens (fundamentally estrone). As change happens essentially in the stromal cells of fat tissue, ooestrogen creation will be expanded in large PCOS patients. This transformation brings about constant input at the nerve center and pituitary organ, as opposed to the ordinary vacillations in criticism saw within the sight of a developing follicle and quickly changing degrees of estradiol[23]. Unopposed oestrogen incitement of the endometrium may prompt endometrial hyperplasia. Expanded insulin opposition has been related with a few issues including Type-IIdiabetes mellitus, hypertension, dyslipidemia, and cardiovascular ailment. Insulin opposition because of hereditary anomalies or potentially expanded fat tissue adds to follicular atresia in the ovaries just as the advancement of acanthosis nigricans in the skin. Insulin invigorate amalgamation and emission of VLDL in the liver coming about in hypertriglyceridemia, which thus improves post-prandial aggregation of lipoproteins (LDL,VLDL) in plasma with bringing down of HDL cholesterol[24].

Ladies with PCOS show diminished sex hormone-restricting globulin (SHBG) levels. This glycoprotein, delivered in the liver, ties most sex steroids. On account of smothered SHBG creation, less coursing androgen is bound and accordingly more stays accessible to tie with endorgan receptors. It caused a few ladies with PCOS will have complete testosterone levels in the typical range, yet will be clinically hyperandrogenic because of raised free testosterone levels. The unbound circling ooestrogen may cause higher endometrial disease chance in PCOS quiet. In some hairbearing territories, androgens invigorate sebaceous organs, and expanded sebum may prompt skin inflammation. In different territories, vellus follicles react to androgens and are changed over to terminal follicles, prompting hirsutism. Terminal hair under the influence of androgens was not before-hand reliant on androgens return to a vellus structure and thinning up top outcomes[25]. Ladies with PCOS are viewed as at expanded danger of premature delivery after either unconstrained or

helped origination. Paces of early pregnancy misfortune are accounted for to be multiple times higher than those in typical ladies (30-half in PCOS versus 10-15% in ordinary ladies)[26]. The finding of high prorenin fixations in juvenile and atretic human follicles, contrasted with develop ones, proposes a potential job of renin in ovarian brokenness. Strangely, in the ovarian tissues from PCOS subjects, the expanded immunehistochemical recoloring of renin, limited in both granulosa and theca cells proposes a job of renin in PCOS. Authoritative of rennin /prorenin to its basic receptor prompts expanded renin movement, expanded plasminogen activator inhibitor-1 creation and instigates cell hypertrophy and vascular fibrosis. These discoveries propose that hyperreninemic state assumes a significant job in the improvement of end-organ harm[27].

Prevalence of PCOS in Adolescent Girls:

PCOS is a common female endocrine problem with 2.2% to 26% predominance. Much of the reports aimed at grown-up ladies with age running from 18 to 45 years. We tentatively considered 460 young women aged 15 to 18 from a private school in Andhra Pradesh, South India, who were clinically examined. In which 72 young ladies with oligomenorrhea as well as hirsutism were accepted by Rotterdam models for biochemical, hormonal, and ultrasonographic evaluation in PCOS.PCOS was defined as the association of every two of the three highlights: (1) Oligo/amenorrhea: the non-appearance of the feminine cycle for 45 days or more and, in addition, ~8 menses annually. (2) Pathological hyperandrogenism: Ferriman and Gallway adjusted (mFG) score 6 or higher. (3) Polycystic ovaries: nearness of > 10 growths, 2-8 mm in measurement, usually followed by an increased ovarian volume of > 10 cm (3), and a dense stroma reverberation in pelvic ultrasound philtre.Out of 460 young adults, one (0.22 %) had oligo / amenorrhea with clinical hyperandrogenism, 29 (6.30 %) had oligomenorrhea with polycystic ovaries, one (0.22 %) had polycystic ovaries with clinical hyperandrogenism, and 11 (2.39 %) had oligomenorrhea with polycystic ovaries with clinical hyperandrogenism. In this way, 42 (9.13%) young women completed the PCOS steps of Rotterdam, which grew to 50.46 (10.97%) when allocated information was integrated. PCOS pervasiveness of Indian youth is 9.13 %[28].

Diagnosis of Polycystic Ovary Syndrome

The symptomatic workup should start with an exhaustive history and physical assessment. Clinicians should concentrate on the patient's menstrual history, any vacillations in the patient's weight and their effect on PCOS indications, and cutaneous discoveries (e.g., terminal hair, skin break out, alopecia, acanthosis nigricans and skin labels)[29].

- **NIH standards**: In 1990, an NIH-supported workshop suggested that a patient should have PCOS on the off risk of developing oligo-ovulation, signs of androgen excess (clinical or biochemical) and related factors that would induce polycystic ovaries[30].
- **Rotterdam models**: In 2003, an agreement workshop conducted in Rotterdam revealed that PCOS would be accessible if any 2 out of 3 steps were met including oligo-ovulation as well as anovulation, androgen overabundance and polycystic ovaries (By gynaecological ultrasound)[31].
- **Androgen abundance PCOS Society standards**: In 2006, the Androgen Overload PCOS Society proposed to fix the indicative guidelines for the whole following activity, including overabundance of androgen, oligo-ovulation / anovulation, polycystic ovaries and other substances that might induce abundance of androgen activity.[32].

NON-PHARMACOLOGICAL MANAGEMENT OF INFERTILITY IN PCOS

- **Changes in Lifestyle:** Change in way of life is considered administration for ladies with polycystic ovarian ailment. The principle focus of way of life changes is anticipation of weight put on and advancing weight reduction where required[33,34-35]. The richness rate are lower in those ladies having a BMI ≥ 30-32kg/m^2,and way of life intercession benefits broaden well past fruitfulness and incorporate Diabetes mellitus Type-IIavoidance.

- **Weight Management**: The goal of women with polycystic ovarian disorder is to be thinner than women without polycystic ovarian disorder and to put on more weight than normal women. Excess weight raises the likelihood of PCOS formation and raises the clinical nature of the disease by worsening the levels of androgen and insulin[36,37-38]. In PCOS[38,39-40], overabundance weight literally extends the severity of the conceptual, emotional, and metabolic highlights. In addition to the apparent challenges in controlling proven weight overabundance, there is a way to counteract weight gain.Additionally, weight misfortune tends to bring remarkable benefits to most ladies with PCOS who are overweight as of now. There are a large number of thin, unregulated preliminaries demonstrating that the weight loss attained during life reduces stomach fat, hyperandrogenism and IR and increases lipid profiles, ovulation, menstrual cyclicity, maturity, DM2 and CVD chance elements, and mental well-being in overweight women with PCOS[41,42-44]. In addition, a decrease of as meagre as 5% of absolute body weight occurred among women with PCOS and overabundance weight to increase the result weight[45-68].

Consequently, the way of life of the executive is beneficial in working on weight loss and weight gain prevention, and is first-line therapy for a large proportion of PCOS people. By taking mediation, the physiological hazard factors associated with PCOS, including hypertension, IR and elevated blood glucose levels, should be enhanced if no weight loss occurs[69-71]. Notwithstanding, it is hard to be sure about the viability of way of life intercessions in ladies with PCOS, in light of the fact that accessible data depends on little uncontrolled preliminaries that address various results in various subgroups of ladies, and explicit proposals stay indistinct.



Figure 1: Diagnosis of Polycystic Ovary Syndrome.

(CT = Computed Tomography; DHEA-S = Dehydroepiandrosterone Sulfate; FSH = Follicle-Stimulating Hormone; LH = Luteinizing Hormone; MRI = Magnetic Resonance Imaging; OGTT = Oral Glucose Tolerance Test; PCOS = Polycystic Ovary Syndrome; TSH = Thyroid-stimulating hormone.)

Ovulatory brokenness is one of the most well-known reasons for conceptive disappointment in sub-prolific in fruitless couples. The best starting cure for the overwhelming greater part of an ovulatory barren lady is clomiphene citrate. In 80 % of women, half of whom completed pregnancy during care, the main clinical preliminary treatment of clomiphene citrate showed fruitful ovulation acceptance[72,73-74]. In subsequent years, the implications of clomiphene citrate have not obviously improved, regardless of the approach of current immunoassays for steroid hormones, improvement in ultrasound advancement for cycle obsequies.

PHARMACOLOGICAL MANAGEMENT OF INFERTILITY IN PCOS

Synthetically, clomiphene citrate (like tamoxifen) is a subordinate non-steroidal triphenylethylene that exhibits both adverse and oestrogen agonist properties[75]. All and all, agonist oestrogen activities are shown only as the endogenous oestrogen levels are extremely low. Anyway, clomiphene citrate acts solely as a significant opponent of oestrogen. In the liver, clomiphene citrate is flushed and released into the stool. After about 6 days, about 85 % of the managed component is disposed of, notwithstanding the fact that the following may remain for longer in the dissemination[76]. Clomiphene citrate, as currently made, is a racemic blend of two distinct stereoisomers, enclomiphene and zuclomiphene. Available data suggests that enclomiphene is the most intense isomer and is essentially responsible for clomiphene citrate's ovulation-inciting operation[77]. After grouping, enclomiphene levels grow rapidly and plunge before long to imperceptible fixations. Zuclomiphene is certainly more increasingly released. Levels of this less complex isomer remain visible in the flow for more than a month after treatment, and may persist over consecutive treatment patterns; however, there is little evidence of any meaningful clinical effect.

Mode of Action

Simple oestrogen comparability allows for clomiphene citrate to attach to oestrogen receptors(ER) across the whole regenerative system. In either case, clomiphene citrate, rather than oestrogen, binds atomic ER for an all-inclusive timeframe and ultimately exhausts ER fixations by meddling with the usual ER recharging process. Adequacy of the drug in ovulation enlistment can be credited to hypothalamic-level activities. Nerve centre fatigue ER forestalls proper understanding of oestrogen streaming levels. Decreased amounts of oestrogen-negative critique activate traditional compensatory mechanisms that adjust pulsatile hypothalamic GnRH discharge to improve increased pituitary gonadotropin discharge and thus drives ovarian follicular operation. Clomiphene citrate therapy produces GnRH beat frequency[78] in ovulatory ladies. In anovulatory women with polycystic ovarian condition (PCOS), in whom the recurrence of the GnRH beat is now oddly high, therapy with citrate clomiphene extends beat adequacy but not recurrence[79]. During treatment with clomiphene citrate, both LH and FSH levels rise; dropping again after the 5-day course of treatment is completed after operating the mill[80]. In productive treatment periods at least one prevailing follicle grows and produces a rising tide of E2 that eventually causes flood and ovulation of the midcycle LH.

Late research indicates that letrozole, an inhibitor of orally responsive aromatase, may have potential as an ovulation-initiating specialist[81,82]. In comparison to the focal activities of clomiphene citrate and tamoxifen, letrozole acts to impede the development of ovarian follicular E2, but the final result is comparable to a decrease in the activity of focal

oestrogen feedback that invigorates a compensatory rise in the discharge of pituitary gonadotropin.

Treatment Regimen

- **Standard Therapy :-**Clomiphene citrate controlled orally, typically starting from the third to fifth day after the start of unconstrained or progestin-prompted menses; ovulation rates, rates of origination and outcomes of birth are analogous in either case when the therapy begins on cycle day 2, 3, 4 or 5[83]. Despite the fact that the portion needed for ovulation is correlated with body weight, there is no solid method for reliably predicting what portion in a person lady would be necessary[84]. Consequently, the approval of ovulation through clomiphene citrate contributes to an empirical incremental titration in an attempt to create the smallest potent portion for each individual.

Treatment typically continues every day for 5 back to back days with a lone 50 mg medication, growing by 50 mg changes in the subsequent periods before ovulation is triggered. Despite the fact that dosages in excess of 100 mg / day are not supported by the Food and Drug Administration (FDA), the heavy portion of clomiphene citrate varies from 50 mg / day to 250 mg / day. Lower dosages (e.g. 12.5 mg / day to 25 mg / day) warrant a preliminary in women who display great affectability to clomiphene citrate or develop large ovarian pimples reliably, interfering with superb cyclic therapy[85]. Most ladies ovulate in the light of 50 mg (52%) or 100 mg (22%) treatment; higher dosages have been used, but they are often less frequently fruitful (150 mg, 12%; 200 mg, 7%: 250 mg, 5%)[86]. Any anovulatory ladies with clomiphene citrate resistants who neglect to respond to a regular multi-day treatment protocol may respond to longer courses (8 days) of clomiphene citrate treatment[87], but such treatment should be viewed as only when elective exogenous gonadotropin treatment is discarded.

- **Alternative and Combination Treatment Regimens:-**Many ladies who show healthy or hard-headed treatment with standard clomiphene citrate can ovulate in the light of elective treatment regimens. A choice between them should not be arbitrary, but relies on clear components of the historical implications of test facility evaluation of the patient, and additionally on perception in previous unsuccessful periods of clomiphene citrate therapy. Additionally, these regimens should not be deemed necessary for the use of tougher therapeutic methods (e.g., exogenous gonadotropins). They are all important decisions that warrant thinking, based on the age, interests, accessible facilities, and danger tolerance of the patient.

- **Insulin Sensitizing Agents:-**Insulin obstruction and hyperinsulinemia in females with PCOS are frequent highlights. Most ladies with PCOS will react to the citrate of clomiphene, but several will prove safe and avoid elective care at last. Among these there would be an apparent insulin obstacle to a massive dominant part[88]. In multiple amenorrheic PCOS women, insulin sharpening specialists (e.g., metformin) alone may recover menstrual and cyclic ovulation, despite the fact that they are not officially verified by the FDA for this indication.Despite the more significant costs and multifaceted nature of metformin therapy and the recurrence of extreme gastrointestinal symptoms (e.g., queasiness, retching, loosening of the intestines), some prefer to save metformin therapy for persons who initially exhibit imperviousness to clomiphene citrate. In any case, those who fail to ovulate in response to either will respond when the two are used in a mixture[89,90-91]. Since metformin therapy can be hepatic poisonous or entangled with lactic acidosis, it is important to evaluate liver and renal capability before care is developed and monitored during pregnancy, primary evidence indicates that it can reduce the risk of unconstrained premature birth and gestational diabetes in women with PCOS.[92,93].

- **Clomiphene and hCG:-**While exogenous hCG has been used in Clomiphene citrate-instigated cycles to cause ovulation and define the optimal opportunity to conduct intrauterine insemination (IUI), the preparation is difficult to legitimise on a regular basis. Treatment requires exorbitant observation of typically futile sequential transvaginal ultrasonic measurement. The mean pinnacle estimation of the preovulatory follicle in fruitful clomiphene citrate prompted ovulatory cycle ranges anywhere in the region of 19 and 30 mm (middle width: 25mm)[94], thereby finding it difficult to establish the perfect possibility to control hCG. In particular , two randomised preliminaries have shown that IUI is no more effective than IUI conducted after the discovery of the endogenous LH flood[95,96],after exogenous hCG-set off ovulationin clomiphene citrate cycles incited. Therefore, the use of exogenous hCG could be better limited to those women who need intrauterine insemination (IUI) and in whom a mid-cycle flood of Luteinizing hormone (LH) cannot be identified reliably.

- **Clomiphene and Glucocorticoids:-**In certain clomiphene citrate healthy Polycystic ovarian disorder ladies, expansion of glucocorticoids (e.g., dexamethasone 0.5 mg or 5 mg hs of prednisolone) into clomiphene citrate care regimen can prompt ovulation when clomiphene citrate alone has crackled. Corresponding glucocorticoid therapy may be focused on the empiric > 200µg / dL[97]or serum dehydroepiandrosterone sulphate fixation. Treatment should continue (three to six cycles) when it is fruitful and should be suspended immediately if it is not.There is no indication that the glucocorticoid therapy has any major effects or risks whether given with the dosages or seen across the duration.

- **Clomipheme and Gonadotrophins: -**Clomiphene citrate safe anovulatory women who ultimately require exogenous gonadotropin to ovulate and those with unexplained barrenness may benefit from a preliminary treatment of successive clomiphene citrate / gonadotropin using either conventional menotropins (hMG) or FSH[98]filtered or recombinant. Given the costs and risks of treatment with exogenous gonadotropin, treatment should be offered uniquely by cycle incorporating a standard routine of clomiphene citrate treatment (50mg / day to 100mg / day, cycle days 5-9), trailed by low hMG or FSH portion (75IU / day, cycle days 9-12). From that point on, care is individualised, as with the customary care of gonadotropin, in terms of transvaginal ultrasound evaluations. Cycle pregnancy for this approach is as that done for gonadotropins alone, but the portion and duration of care and the corresponding costs of study may be reduced significantly. The other apparent alternative is therapy of exogenous gonadotropins alone.Clomiphene citrate healthy anovulatory ladies are always very affectable to low gonadotropin component and therapy should be prepared if possible to achieve ovulation of yet a lone follicle growth. There's no evidence of deliberate superovulation in fruitless anovulatory ladies.

METFORMIN VERSUS PLACEBO IN POLYCYSTIC OVARY SYNDROME (PCOS)

- **Ovulation Rates:-**Metformin out conducted false therapy among and large people with PCOS (characterised as all women with PCOS in the main analysis or tests, paying no attention to the representation or affectability of clomiphene citrate weight list) ($p < 0.001$), among women with PCOS and BMI 30 kg / m2 ($p < 0.001$), with BMI 30 kg / m2 ($p= 0.007$)[99], and among women with non-clomiphene citrate-safe[100]. Between big and big women with PCOS (I2 = 69%) and among those with a BMI of 30 kg / m2 (I2 = 88%), there was considerable factual heterogeneity. In CCR ladies, ovulation rates were similar between bunches.

- **Pregnancy Rates:-**Metformin outflanked false therapy among large women with PCOS ($p < 0.001$), without observable heterogeneity ($I2= 0$) and among those with a BMI of 30 kg / m2 ($p<0.001$) with limited statistical heterogeneity ($I2= 40$ %), but no difference was observed in those with a BMI of 30 kg / m2, in women with clomiphene citrate-guileless, women with CCR PCOS or women with non-CCR PCOS.
- **Live Birth Rates:-** There was no contrast among metformin and fake treatment in general ladies with PCOS, in ladies with CCR and ladies with a BMI 30 kg/m^2.
- **Miscarriage Rates:-**There was no contrast among metformin and fake treatment in generally speaking ladies with PCOS.
- **Adverse Effects:-**Metformin instigated more gastrointestinal-related unfavorable occasions contrasted and fake treatment ($p<0.001$), with minimal measurable heterogeneity ($I2 = 25\%$).

Metformin verses Clomiphene Citrate

- **Ovulation Rates:-**Clomiphene citrate beat metformin among broadly speaking women with PCOS (in the related investigation or trials, defined as all women with PCOS, paying no attention to the weight file ($p<0.001$) and among those with a BMI of 30 kg / m2 ($p<0.001$). Both big and big ladies with PCOS ($I2 = 78$ %), statistical heterogeneity was significant. Including those with a BMI of 30 kg / m2, clomiphene citrate was virtually similar to metformin.
- **Pregnancy Rates:-**Clomiphene citrate out performed metformin among PCOS women in general ($p= 0.018$) and 30 kg / m2 ($p < 0.001$) BMI women. Be it as it might, in general ladies with PCOS ($I2= 91$ %) there was massive observable heterogeneity identified. Among those with a BMI of 30 kg / m2 metformin out performed clomiphene citrate; in any event, this relied on a solitary observation ($p=0.003$).
- **Live Birth Rates:-**In generally speaking ladies with PCOS, clomiphene citrate and metformin were nearly similar, with detectable heterogeneity. In those with a BMI of 30 kg / m2 ($p<0.002$) without observable heterogeneity ($I2 = 0$), clomiphene citrate was stronger than metformin for live birth rate. In those with a BMI of 30 kg / m2, Metformin outflanked clomiphene citrate; this was, however, based on a single study ($p<0.001$).
- **Adverse Effects:-**There was no difference between metformin and clomiphene citrate in broadly speaking ladies with PCOS in separate pregnancy rates (without detectable heterogeneity) and in ineffective birth rate (with factual heterogeneity).

Metformin Plus Clomiphene Citrate Versus Clomiphene Citrate Alone

- **Ovulation Rates :-**In addition to clomiphene citrate, metformin was stronger than clomiphene citrate alone among general females with PCOS (characterised as all females with PCOS in the related investigation or trials, paying no attention to weight index (BMI) ($p<0.001$) and those with BMI 30 kg / m2 ($p=0.009$), BMI 30 kg / m2 ($p<0.001$), PCOS ($p<0.001$) with clomiphene citrate-safe (CCR) and non-CCR PCOS ($p<0.001$). Be that as it might, apart from among women with CCR PCOS ($I2 = 0$), there was enormous statistical variability in these selection associations ($I2 > 65$ %). There was no distinction between the two medicines in ladies with clomiphene citrate- susceptible to PCOS.

- **Pregnancy Rates:-**In addition to clomiphene citrate, metformin was stronger than clomiphene citrate alone amongst typically PCOS-positive people with a BMI of 30 kg / m2 [101]. In all these selection examinations (I2 > 58 %), apart from those with a BMI of 30 kg / m2 (I2= 40 %) and those with CCR PCOS (I2= 0), there was tremendous statistical heterogeneity. In comparison to clomiphene citrate and clomiphene citrate alone, there was no difference between those with a BMI 30 kg / m2, non-CCR PCOS, and those with mysterious clomiphene citrate affectability.
- **Live Birth Rates:-**In addition to clomiphene citrate, metformin was stronger for extending the live birth rate of women with CCR PCOS (p=0.03) than clomiphene citrate alone, without observable heterogeneity (I2=0). In those with a BMI 30 kg / m2, a BMI 30 kg / m^2 and a clomiphene citrate-innocent PCOS, the live birth rate was equal between the two gatherings by and wide. In general speaking ladies with PCOS and those with a BMI of 30 kg / m2 the premature delivery rates were comparable. Similarly, various pregnancy rates were comparable in women with PCOS, those with BMI 30 kg / m2 and those with clomiphene citrate mysterious affectability.
- **Adverse Effects:** Clomiphene citrate causes fever, gastrointestinal problems in contrast to metformin.

Metformin Plus Clomiphene Citrate versus Metformin Alone

- Metformin in addition to clomiphene citrate was better than metformin alone among by and large ladies with PCOS inovulation rates[102], pregnancy rates[103]and live birth rates.
- **Adverse Effects:** There was no distinction between metformin in addition to clomiphene citrate and metformin alone for unsuccessful labor rate or unfavourable occasions in by and large ladies with PCOS.

Surgical Management of Infertility in PCOS

- **Ovarian Drilling:** In addition to clomiphene citrate, metformin was stronger for extending the live birth rate of women with CCR PCOS (p=0.03) than clomiphene citrate alone, without observable heterogeneity (I2=0). In those with a BMI 30 kg / m2, a BMI 30 kg / m2 and a clomiphene citrate-innocent PCOS, the live birth rate was equal between the two gatherings by and wide. In general speaking ladies with PCOS and those with a BMI of 30 kg / m2 the premature delivery rates were comparable. Similarly, various pregnancy rates were comparable in women with PCOS, those with BMI 30 kg / m2 and those with clomiphene citrate mysterious affectability. Most births have a smaller risk[104]. Ovarian penetration may help to re-establish immunity to clomiphene citrate therapy at the point that it does not contribute to unconstrained ovulation. For clomiphene healthy anovulatory patients, ovarian penetration is a fair option, but the intermittent consequences of therapy and the chance of postoperative attachments or decreased ovarian save should be purposely recognised.

CONCLUSIONS

Clomiphene citrate is the ideal introductory therapy for most ladies whose ovulatory brokenness (anovulation, luteal stage insufficiency) is linked to barreness. Clomiphene citrate therapy, combined with suitably orchestrated IUI, often improves the reproductive period of couples of unexplained barrenness. Treatment of clomiphene citrate should be confined to the base viable component and to approximately six ovulatory cycles by and wide. Inability to picture ovulation following successful initiation of clomiphene citrate is a warning for additional evaluation to prevent any causes for barrenness.Mixing therapies with clomiphene citrate and multiple operators (metformin, glucocorticoids, exogenous

gonadotropins) might be effective as therapy with clomiphene citrate alone neglects ovulation instigation. Elective clomiphene citrate programmes provide care with aromatase inhibitors or exogenous gonadotropins for women and ovarian penetration in selected cases. To guarantee its adequacy in ovulation enlistment, clomiphene citrate therapy should be observed (BBT, serum P fixation, urinary LH discharge). Symptoms of treatment with clomiphene citrate are usually moderate and very lasting. Symptoms of clomiphene citrate treatment are commonly gentle and very much endured. The chief danger of clomiphene citrate treatment is an expanded frequency of various growth (<10%).

REFERENCES

1. *El-Sharkawy AA, Abdelmotaleb GS, Aly MK, Kabel AM. Effect of metformin on sleep disorders in adolescent girls with polycystic ovarian syndrome. Journal of pediatric and adolescent gynecology. 2014 Dec 1;27(6):347-52.*
2. *Nafiye Y, Sevtap K, Muammer D, Emre O, Senol K, Leyla M. The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome. Fertility and sterility. 2010 Apr 1;93(6):1864-9.*
3. *Louwers YV, Laven JS. Characteristics of polycystic ovary syndrome throughout life. Therapeutic Advances in Reproductive Health. 2020 Mar;14:2633494120911038.*
4. *Allahbadia GN, Merchant R. Polycystic ovary syndrome and impact on health. Middle East Fertility Society Journal. 2011 Mar 1;16(1):19-37.*
5. *Boomsma CM, Fauser BC, Macklon NS. Pregnancy complications in women with polycystic ovary syndrome. InSeminars in reproductive medicine 2008 Jan (Vol. 26, No. 01, pp. 072-084). © Thieme Medical Publishers.*
6. *Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC medicine. 2010 Dec;8(1):1-0.*
7. *Palomba S, Santagni S, Falbo A, La Sala GB. Complications and challenges associated with polycystic ovary syndrome: current perspectives. International journal of women's health. 2015;7:745.*
8. *Legro RS, Strauss III JF. Molecular progress in infertility: polycystic ovary syndrome. Fertility and sterility. 2002 Sep 1;78(3):569-76.*
9. *Doi SA, Al-Zaid M, Towers PA, Scott CJ, Al-Shoumer KA. Ovarian steroids modulate neuroendocrine dysfunction in polycystic ovary syndrome. Journal of endocrinological investigation. 2005 Jan;28(1):882-92.*
10. *Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstetrical & gynecological survey. 2004 Feb 1;59(2):141-54.*
11. *Balen AH, Conway GS, Kaltsas G, Techatraisak K, Manning PJ, West C, Jacobs HS. Andrology: Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Human reproduction. 1995 Aug 1;10(8):2107-11.*
12. *Kiddy DS, Sharp PS, White DM, Scanlon MF, Mason HD, Bray CS, Polson DW, Reed MJ, Franks S. Differences in clinical and endocrine features between obese and non□obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clinical endocrinology. 1990 Feb;32(2):213-20.*

13. *Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-DeHoff RM, Johnson BD, Vaccarino V. Withdrawn: postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health—National heart, lung, and blood institute sponsored women's ischemia syndrome evaluation. The Journal of Clinical Endocrinology & Metabolism. 2008 Apr 1;93(4):1276-84.*

14. *STRAUSS III JF. Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome. Annals of the New York Academy of Sciences. 2003 Nov;997(1):42-8.*

15. *Lee TT, Rausch ME. Polycystic ovarian syndrome: role of imaging in diagnosis. Radiographics. 2012 Oct;32(6):1643-57.*

16. *Nafiye Y, Sevtap K, Muammer D, Emre O, Senol K, Leyla M. The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome. Fertility and sterility. 2010 Apr 1;93(6):1864-9.*

17. *Sharquie KE, Al-Bayatti AA, Al-Ajeel AI, Al-Bahar AJ, Al-Nuaimy AA. Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome. Saudi medical journal. 2007 Jul 1;28(7):1039.*

18. *Pasquali R, Gambineri A. Insulin-sensitizing agents in polycystic ovary syndrome. European journal of endocrinology. 2006 Jun 1;154(6):763-75.*

19. *Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators of inflammation. 2010 Oct;2010.*

20. *González F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2006 Jan 1;91(1):336-40.*

21. *Gleicher N, Weghofer A, Lee IH, Barad DH. FMR1 genotype with autoimmunity-associated polycystic ovary-like phenotype and decreased pregnancy chance. PloS one. 2010 Dec 16;5(12):e15303.*

22. *Kelly CJ, Stenton SR, Lashen H. Insulin-like growth factor binding protein-1 in PCOS: a systematic review and meta-analysis. Human reproduction update. 2011 Jan 1;17(1):4-16.*

23. *Schorge JO, Williams JW. Williams gynecology. McGraw-Hill Medical,; 2008.*

24. *Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Human reproduction update. 2007 Nov 1;13(6):527-37.*

25. *Singh B, Panda S, Nanda R, Pati S, Mangaraj M, Sahu PK, Mohapatra PC. Effect of metformin on hormonal and biochemical profile in PCOS before and after therapy. Indian Journal of Clinical Biochemistry. 2010 Oct 1;25(4):367-70.*

26. *Chhabra S, Gautam RK, Kulshreshtha B, Prasad A, Sharma N. Hirsutism: A clinico-investigative study. International journal of trichology. 2012 Oct;4(4):246.*

27. *Khattab S, Mohsen IA, Foutouh IA, Ramadan A, Moaz M, Al-Inany H. Metformin reduces abortion in pregnant women with polycystic ovary syndrome. Gynecological Endocrinology. 2006 Jan 1;22(12):680-4.*

28. *Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of polycystic ovarian syndrome in Indian adolescents. Journal of pediatric and adolescent gynecology. 2011 Aug 1;24(4):223-7.*

29. *Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2013 Dec 1;98(12):4565-92.*

30. *Carmina E. PCOS: metabolic impact and long-term management. Minerva ginecologica. 2012 Dec 1;64(6):501-5.*

31. *Azziz R. Diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. The Journal of Clinical Endocrinology & Metabolism. 2006 Mar 1;91(3):781-5.*

32. *Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC medicine. 2010 Dec;8(1):1-0.*

33. *Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertility and sterility. 2009 Dec 1;92(6):1966-82.*

34. *Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BG, Wong JL, Norman RJ, Costello MF. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. The Medical Journal of Australia. 2011 Sep 19;195(6):S65.*

35. *Harrison CL, Lombard CB, Moran LJ, Teede HJ. Exercise therapy in polycystic ovary syndrome: a systematic review. Human reproduction update. 2011 Mar 1;17(2):171-83.*

36. *Barbosa G, de Sá LB, Rocha DR, Arbex AK. Polycystic ovary syndrome (PCOS) and fertility. Open Journal of Endocrine and Metabolic Diseases. 2016 Jan 12;6(1):58-65.*

37. *Rachoń D, Teede H. Ovarian function and obesity—interrelationship, impact on women's reproductive lifespan and treatment options. Molecular and cellular endocrinology. 2010 Mar 25;316(2):172-9.*

38. *Acién P, Quereda F, Matallín P, Villarroya E, López-Fernández JA, Acién M, Mauri M, Alfayate R. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertility and sterility. 1999 Jul 1;72(1):32-40.*

39. *Kriedt KJ, Alchami A, Davies MC. PCOS: diagnosis and management of related infertility. Obstetrics, Gynaecology & Reproductive Medicine. 2019 Jan 1;29(1):1-5.*

40. *Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN, PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2006 Jan 1;91(1):48-53.*

41. *Mohammad MB, Seghinsara AM. Polycystic ovary syndrome (PCOS), diagnostic criteria, and AMH. Asian Pacific journal of cancer prevention: APJCP. 2017;18(1):17.*

42. *Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. The journal of clinical endocrinology & metabolism. 1999 Jan 1;84(1):165-9.*

43. *Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Human Reproduction (Oxford, England). 1998 Jun 1;13(6):1502-5.*

44. *Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. The Journal of Clinical Endocrinology & Metabolism. 1999 Apr 1;84(4):1470-4.*

45. *Moran LJ, Noakes M, Clifton PM, Tomlinson L, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2003 Feb 1;88(2):812-9.*

46. *Thomson RL, Buckley JD, Lim SS, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertility and sterility. 2010 Oct 1;94(5):1812-6.*

47. *Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Human Reproduction (Oxford, England). 1998 Jun 1;13(6):1502-5.*

48. *Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. The Journal of Clinical Endocrinology & Metabolism. 1999 Apr 1;84(4):1470-4.*

49. *Moran LJ, Noakes M, Clifton PM, Tomlinson L, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2003 Feb 1;88(2):812-9.*

50. *Thomson RL, Buckley JD, Lim SS, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertility and sterility. 2010 Oct 1;94(5):1812-6.*

51. *Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale PO, Løvik A, Birkeland K. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism. 1995 May 1;44(5):611-6.*

52. *Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, Norman RJ. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Human reproduction. 1995 Oct 1;10(10):2705-12.*

53. *Crave JC, Fimbel S, Lejeune H, Cugnardey NA, Dechaud H, Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. The Journal of Clinical Endocrinology & Metabolism. 1995 Jul 1;80(7):2057-62.*

54. *Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Human reproduction. 2003 Sep 1;18(9):1928-32.*

55. *Gambineri A, Pelusi C, Genghini S, Morselli□Labate AM, Cacciari M, Pagotto U, Pasquali R. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clinical endocrinology. 2004 Feb;60(2):241-9.*

56. *Guzick DS, Wing R, Smith D, Berga SL, Winters SJ. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertility and sterility. 1994 Apr 1;61(4):598-604.*

57. *Holte J, Bergh T, Berne CH, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 1995 Sep 1;80(9):2586-93.*

58. *Jakubowicz DJ, Nestler JE. 17α-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. The Journal of Clinical Endocrinology & Metabolism. 1997 Feb 1;82(2):556-60.*

59. *Kiddy DS, Hamilton□Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clinical endocrinology. 1992 Jan;36(1):105-11.*

60. *Kiddy DS, Hamilton□Fairley D, Seppälä M, Koistinen R, James VH, Reed MJ, Franks S. Diet□induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin□like growth factor□I. Clinical endocrinology. 1989 Dec;31(6):757-64..*

61. *Moran LJ, Noakes M, Clifton PM, Wittert GA, Belobrajdic DP, Norman RJ. C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2007 Aug 1;92(8):2944-51.*

62. *Moran LJ, Noakes M, Clifton PM, Wittert GA, Williams G, Norman RJ. Short-term meal replacements followed by dietary macronutrient restriction enhance weight loss in polycystic ovary syndrome. The American journal of clinical nutrition. 2006 Jun 1;84(1):77-87.*

63. *Pasquali R, ANTENUCCI D, CASIMIRRI F, VENTUROLI S, PARADISI R, FABBRI R, BALESTRA V, MELCHIONDA N, BARBARA L. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. The Journal of Clinical Endocrinology & Metabolism. 1989 Jan 1;68(1):173-9.*

64. *Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2000 Aug 1;85(8):2767-74.*

65. *Qublan HS, Yannakoula EK, Al-Qudah MA, El-Uri FI. Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study. Saudi medical journal. 2007 Nov 1;28(11):1694-9.*

66. *Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertility and sterility. 2004 Mar 1;81(3):630-7.*

67. *Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Human reproduction. 2006 Jan 1;21(1):80-9.*

68. *Van Dam EW, Roelfsema F, Veldhuis JD, Helmerhorst FM, Frölich M, Meinders AE, Krans HM, Pijl H. Increase in daily LH secretion in response to short-term calorie restriction in obese women with PCOS. American Journal of Physiology-Endocrinology and Metabolism. 2002 Apr 1;282(4):E865-72.*

69. *Wahrenberg H, Ek I, Reynisdottir S, Carlström K, Bergqvist A, Arner P. Divergent effects of weight reduction and oral anticonception treatment on adrenergic lipolysis regulation in obese women with the polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 1999 Jun 1;84(6):2182-7.*

70. *Hutchison SK, Stepto NK, Harrison CL, Moran LJ, Strauss BJ, Teede HJ. Effects of exercise on insulin resistance and body composition in overweight and obese women with and without polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2011 Jan 1;96(1):E48-56.*

71. *Poehlman ET, Dvorak RV, DeNino WF, Brochu M, Ades PA. Effects of resistance training and endurance training on insulin sensitivity in nonobese, young women: a controlled randomized trial. The Journal of Clinical Endocrinology & Metabolism. 2000 Jul 1;85(7):2463-8.*

72. *Robert R. Reduction in Obesity and Related Comorbid Conditions after Diet-Induced Weight Loss or Exercise-Induced Weight Loss in Men: A Randomized, Controlled Trial. Ann. Intern. Med.. 2000;133:92-103.*

73. *Greenblatt RB. Chemical induction of ovulation. Fertility and sterility. 1961 Sep 1;12(5):402-4.*

74. *Zimmerman LD, Setton R, Pereira N, Rosenwaks Z. Contemporary Management of Polycystic Ovarian Syndrome. Clinical obstetrics and gynecology. 2019 Jun 1;62(2):271-81.*

75. *Clark JH, Markaverich BM. The agonistic-antagonistic properties of clomiphene: a review. Pharmacology & therapeutics. 1981 Jan 1;15(3):467-519.*

76. *Mikkelson TJ, Kroboth PD, Cameron WJ, Dittert LW, Chungi V, Manberg PJ. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertility and sterility. 1986 Sep 1;46(3):392-6.*

77. *Van Campenhout J, Borreman ET, Wyman H, Antaki A. Induction of ovulation with cisclomiphene. American Journal of Obstetrics and Gynecology. 1973 Feb 1;115(3):321-7.*

78. *KERIN JF, LIU JH, PHILLIPOU G, Yen SS. Evidence for a hypothalamic site of action of clomiphene citrate in women. The Journal of Clinical Endocrinology & Metabolism. 1985 Aug 1;61(2):265-8.*

79. *Kettel LM, Roseff SJ, Berga SL, Mortola JF, Yen SS. Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovary syndrome. Fertility and sterility. 1993 Mar 1;59(3):532-8.*

80. *Rebar RH, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. The Journal of clinical investigation. 1976 May 1;57(5):1320-9.*

81. *Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertility and sterility. 2001 Feb 1;75(2):305-9.*

82. *Fisher SA, Reid RL, Van Vugt DA, Casper RF. A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. Fertility and sterility. 2002 Aug 1;78(2):280-5.*

83. *Wu CH, Winkel CA. The effect of therapy initiation day on clomiphene citrate therapy. Fertility and sterility. 1989 Oct 1;52(4):564-8.*

84. *Lobo RA, Granger LR, Davajan V, Mishell Jr DR. An extended regimen of clomiphene citrate in women unresponsive to standard therapy. Fertility and sterility. 1982 Jun 1;37(6):762-6.*

85. *Dodge ST, Strickler RC, Keller DW. Ovulation induction with low doses of clomiphene citrate. Obstetrics and gynecology. 1986 Mar 1;67(3 Suppl):63S-5S.*

86. *Gysler M, March CM, Mishell Jr DR, Bailey EJ. A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. Fertility and sterility. 1982 Feb 1;37(2):161-7.*

87. *Lobo RA, Granger LR, Davajan V, Mishell Jr DR. An extended regimen of clomiphene citrate in women unresponsive to standard therapy. Fertility and sterility. 1982 Jun 1;37(6):762-6.*

88. *Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 1998 Aug 1;83(8):2694-8.*

89. *Heard MJ, Pierce A, Carson SA, Buster JE. Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertility and sterility. 2002 Apr 1;77(4):669-73.*

90. *Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine. 1998 Jun 25;338(26):1876-80.*

91. *Velázquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstetrics & Gynecology. 1997 Sep 1;90(3):392-5.*

92. *Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertility and sterility. 2001 Jan 1;75(1):46-52.*

93. *Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertility and sterility. 2002 Mar 1;77(3):520-5.*

94. *Opsahl MS, Robins ED, O'Connor DM, Scott RT, Fritz MA. Characteristics of gonadotropin response, follicular development, and endometrial growth and maturation across consecutive cycles of clomiphene citrate treatment. Fertility and sterility. 1996 Oct 1;66(4):533-9.*

95. *Deaton JL, Clark RR, Pittaway DE, Herbst P, Bauguess P. Clomiphene citrate ovulation induction in combination with a timed intrauterine insemination: the value of urinary luteinizing hormone versus human chorionic gonadotropin timing. Fertility and sterility. 1997 Jul 1;68(1):43-7.*

96. *Zreik TG, García-Velasco JA, Habboosh MS, Olive DL, Arici A. Prospective, randomized, crossover study to evaluate the benefit of human chorionic gonadotropin–timed versus urinary luteinizing hormone–timed intrauterine inseminations in clomiphene citrate–stimulated treatment cycles. Fertility and sterility. 1999 Jun 1;71(6):1070-4.*

97. *Daly DC, Walters CA, Soto-Albors CE, Tohan N, Riddick DH. A randomized study of dexamethasone in ovulation induction with clomiphene citrate. Fertility and Sterility. 1984 Jun 1;41(6):844-8.*

98. *March CM, Tredway DR, Mishell Jr DR. Effect of clomiphene citrate upon amount and duration of human menopausal gonadotropin therapy. American journal of obstetrics and gynecology. 1976 Jul 1;125(5):699-704.*

99. *Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin□sensitising drugs (metformin, rosiglitazone, pioglitazone, D□chiro□inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews. 2012(5).*

100. *Creanga AA, Bradley HM, McCormick C, Witkop CT. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstetrics & Gynecology. 2008 Apr 1;111(4):959-68.*

101. *Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Human reproduction update. 2007 Nov 1;13(6):527-37.*

102. *Palomba S, Pasquali R, Orio Jr F, Nestler JE. Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head□to□head randomized controlled studies and meta-analysis. Clinical endocrinology. 2009 Feb;70(2):311-21.*

103. *Farquhar C, Brown J, Marjoribanks J. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane database of systematic reviews. 2012(6).*

104. *Lebbi I, Ben Temime R, Fadhlaoui A, Feki A. Ovarian drilling in PCOS: is it really useful?. Frontiers in surgery. 2015 Jul 17;2:30.*